Table 1 Patient characteristic receiving MRC or RIC regimens.
Variables | Group | MAC N = 2101 (60.8%) | RIC N = 1353(39.2%) | p-value | |
|---|---|---|---|---|---|
Age at CBT, year | Median (range) | 51 (16–80) | 59 (16–79) | <0.001 | *** |
Over 50 | 1090 (51.9%) | 1008 (74.5%) | |||
50 or under | 1011(48.1%) | 345(25.5%) | <0.001 | *** | |
Sex | Male | 1199 (57.1%) | 798 (59.0%) | ||
Female | 902 (42.9%) | 555(41.0%) | 0.28 | ||
ECOG PS score | 0–1 | 1820 (86.6%) | 989 (73.1%) | ||
2–4 | 279 (13.3%) | 360 (26.6%) | <0.001 | *** | |
HCT-CI score | 0–2 | 1627 (77.4%) | 995 (73.5%) | ||
3- | 448 (21.3%) | 325 (24.0%) | <0.001 | *** | |
Disease status | CR1 | 603 (28.7%) | 388 (28.7%) | ||
CR2 | 236 (11.2%) | 136 (10.1%) | |||
CR3- | 25 (1.2%) | 39 (2.9%) | |||
non-CR | 1237 (58.9%) | 789 (58.3%) | 0.003 | ** | |
Disease risk | High | 1262 (60.1%) | 828 (61.2%) | ||
Low | 839 (39.9%) | 524 (38.7%) | 0.51 | ||
Disease type | de novo | 1921 (91.4%) | 1200 (88.7%) | ||
Secondary | 180 (8.6%) | 153 (11.3%) | 0.009 | ** | |
Time from diagnosis to CBT | |||||
<3 months | 292 (13.9%) | 129 (9.5%) | |||
3–6 months | 665 (31.7%) | 306 (22.6%) | |||
>6months | 1143 (54.4%) | 918 (67.8%) | <0.001 | *** | |
HLA mismatch | 0/6 | 87 (4.1%) | 93 (6.9%) | ||
1/6 | 450 (21.4%) | 309 (22.8%) | |||
2/6 | 1549 (73.7%) | 942 (69.6%) | |||
3/6 or more | 15 (0.7%) | 9 (0.7%) | 0.002 | ** | |
GVHD prophylaxis | CyA-based | 442 (21.0%) | 237 (17.5%) | ||
Tac-based | 1633 (77.7%) | 1095 (80.9%) | 0.04 | * | |
Years of CBT | 2010–2015 | 1214 (57.8%) | 883 (65.3%) | ||
2016–2019 | 887 (42.2%) | 470 (34.7%) | <0.001 | *** | |
Median total cell dose (107 cells/kg) | 0.27 | 0.27 | 0.73 | ||
Median CD34+ cell dose (105cells/kg) | 0.9 | 0.87 | 0.13 | ||
Median follow-up of survivors (year) | 3.24 | 3.27 | 0.4 | ||
